A clinical trial at six study sites, including Smilow Cancer Hospital at Yale-New Haven, will investigate a new treatment for small cell lung cancer (SCLC). IMGN901 (lorvotuzumab mertansine), produced by ImmunoGen, is a novel type of treatment that targets CD56, a protein that is expressed by tumors in a number of different cancers, including SCLC. Because IMGN901 specifically targets a tumor protein, the toxic drug is delivered preferentially to cancer cells and is less likely to harm healthy cells. Another drug using a similar mechanism was recently approved for breast cancer.
To find out more about the trial, call 203-200-5864.
ImmunoGen page on IMGN901: http://www.immunogen.com/pipeline/lorvotuzumab-mertansine/